Myriad Gen. erfolgreiche Studie II !!!!!! - 500 Beiträge pro Seite

[to2300]

Jetzt noch schnell in D ordern!!
Kurs 50,6 €

Hier der Text:

Myriad Genetics Reports Phase II Data on Lead Compound MPC-7869 at Recent Cancer Research Meeting
- Clinical Study in Prostate Cancer Patients Reported Safety and Effect on PSA Progression Results -
SALT LAKE CITY, April 26 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) announced today that Phase IIa clinical trial data on its lead cancer compound, MPC-7869 was presented at the recent annual meeting of the American Association for Cancer Research.

The study by lead author Michael B. Lilly, M.D. of Loma Linda University, was entitled, ``Multi-Dose Phase I-IIa Trial of E-7869 in Prostate Cancer Patients: Safety and Time to PSA Progression (TPSAP).`` The presentation reported 4-month findings from 23 late stage prostate cancer patients who went on to receive up to 32 weeks of dosing with MPC-7869. The trial was open- label, using biweekly escalation of MPC-7869 oral daily dose levels. Generally, dose levels increased from 200mg per day to 1200 mg per day during the first 16 weeks. Most patients went on to receive 800mg twice daily for an additional 16 weeks. The safety and tolerance of daily oral doses was reported in the presentation as well as analysis of PSA level data collected throughout the study.

Of the 23 prostate cancer patients enrolled, 13 had a PSA level greater than 5ng/ml and rising (greater than 50% increase over the prior 4-6 months) at entry into the study. Of these, five (39%) had stable PSA values after 120 days of treatment with MPC-7869. Five of the enrolled prostate cancer patients had a PSA level less than 5 ng/ml that was rising at entry into the study. Three of these five (60%) had less than a 50% increase in their PSA level through 120 days of treatment with MPC-7869. In all, 8 of the 18 prostate cancer patients (42%) that had rising PSA levels at study entry experienced either a complete stabilization in PSA level or a reduction in the rate of increase of their PSA level.

The authors conclude that extended daily dosing with MPC-7869 was well- tolerated in late stage prostate cancer patients with a good safety profile and that given results of the analysis of the effect of MPC-7869 on PSA progression in these patients, MPC-7869 should continue to be studied in controlled human clinical trials for adjuvant therapy and chemoprevention of prostate cancer.

``We are very pleased with these exciting results in a disease that is extremely difficult to treat,`` said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. ``Currently, the only treatments available to patients with advanced prostate cancer are for the management of symptoms and offer little in terms of affecting disease progression.``

As part of the AACR presentation, previous studies with MPC-7869 in animal models of both prostate and colon cancer were summarized. Results of MPC-7869 in the TRAMP mouse model of prostate cancer supported the reported clinical data. Of further interest were experiments in the APC min+/- mouse model. These mice develop polyps that are believed to mirror the spontaneous formation of polyps, which are precursors of cancerous tumors, in humans. In this model, MPC-7869 reduced polyp/tumor area by approximately 99%. All of the animals treated with MPC-7869 survived, versus only 27% survival among untreated animals. Although 27% of the untreated animals survived the 180 day study period, they had extensive tumors, while all of the treated animals remained healthy.

Myriad intends to take MPC-7869 through human clinical trials itself, retaining all rights to the drug. Myriad is currently planning further human clinical trials for MPC-7869 that could be initiated later this year. Following a successful development process and regulatory approval to market, Myriad would market the MPC-7869 drug through its own oncology sales force. This 65-person team is currently marketing predictive medicine products, in the fields of breast cancer and colon cancer, to medical and surgical oncologists in cancer centers throughout the United States.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel therapeutic products derived from its proprietary genomic and proteomic technologies. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and markets proprietary predictive medicine and personalized medicine products. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and Syngenta.

The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to uncertainties as to the extent of future government regulation of Myriad Genetics` or Myriad Proteomics` business, uncertainties as to whether Myriad Genetics or Myriad Proteomics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics; the risk that markets will not exist for therapeutic compounds that Myriad Genetics or Myriad Proteomics develops or if such markets exist, that Myriad Genetics or Myriad Proteomics will not be able to sell compounds, which it develops, at acceptable prices

[to2300]

Myriad Genetics Reports Phase II Data on Lead Compound MPC-7869 at Recent Cancer Research Meeting
- Clinical Study in Prostate Cancer Patients Reported Safety and Effect on PSA Progression Results -
SALT LAKE CITY, April 26 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) announced today that Phase IIa clinical trial data on its lead cancer compound, MPC-7869 was presented at the recent annual meeting of the American Association for Cancer Research.

The study by lead author Michael B. Lilly, M.D. of Loma Linda University, was entitled, ``Multi-Dose Phase I-IIa Trial of E-7869 in Prostate Cancer Patients: Safety and Time to PSA Progression (TPSAP).`` The presentation reported 4-month findings from 23 late stage prostate cancer patients who went on to receive up to 32 weeks of dosing with MPC-7869. The trial was open- label, using biweekly escalation of MPC-7869 oral daily dose levels. Generally, dose levels increased from 200mg per day to 1200 mg per day during the first 16 weeks. Most patients went on to receive 800mg twice daily for an additional 16 weeks. The safety and tolerance of daily oral doses was reported in the presentation as well as analysis of PSA level data collected throughout the study.

Of the 23 prostate cancer patients enrolled, 13 had a PSA level greater than 5ng/ml and rising (greater than 50% increase over the prior 4-6 months) at entry into the study. Of these, five (39%) had stable PSA values after 120 days of treatment with MPC-7869. Five of the enrolled prostate cancer patients had a PSA level less than 5 ng/ml that was rising at entry into the study. Three of these five (60%) had less than a 50% increase in their PSA level through 120 days of treatment with MPC-7869. In all, 8 of the 18 prostate cancer patients (42%) that had rising PSA levels at study entry experienced either a complete stabilization in PSA level or a reduction in the rate of increase of their PSA level.

The authors conclude that extended daily dosing with MPC-7869 was well- tolerated in late stage prostate cancer patients with a good safety profile and that given results of the analysis of the effect of MPC-7869 on PSA progression in these patients, MPC-7869 should continue to be studied in controlled human clinical trials for adjuvant therapy and chemoprevention of prostate cancer.

``We are very pleased with these exciting results in a disease that is extremely difficult to treat,`` said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. ``Currently, the only treatments available to patients with advanced prostate cancer are for the management of symptoms and offer little in terms of affecting disease progression.``

As part of the AACR presentation, previous studies with MPC-7869 in animal models of both prostate and colon cancer were summarized. Results of MPC-7869 in the TRAMP mouse model of prostate cancer supported the reported clinical data. Of further interest were experiments in the APC min+/- mouse model. These mice develop polyps that are believed to mirror the spontaneous formation of polyps, which are precursors of cancerous tumors, in humans. In this model, MPC-7869 reduced polyp/tumor area by approximately 99%. All of the animals treated with MPC-7869 survived, versus only 27% survival among untreated animals. Although 27% of the untreated animals survived the 180 day study period, they had extensive tumors, while all of the treated animals remained healthy.

Myriad intends to take MPC-7869 through human clinical trials itself, retaining all rights to the drug. Myriad is currently planning further human clinical trials for MPC-7869 that could be initiated later this year. Following a successful development process and regulatory approval to market, Myriad would market the MPC-7869 drug through its own oncology sales force. This 65-person team is currently marketing predictive medicine products, in the fields of breast cancer and colon cancer, to medical and surgical oncologists in cancer centers throughout the United States.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel therapeutic products derived from its proprietary genomic and proteomic technologies. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and markets proprietary predictive medicine and personalized medicine products. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and Syngenta.

The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to uncertainties as to the extent of future government regulation of Myriad Genetics` or Myriad Proteomics` business, uncertainties as to whether Myriad Genetics or Myriad Proteomics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics; the risk that markets will not exist for therapeutic compounds that Myriad Genetics or Myriad Proteomics develops or if such markets exist, that Myriad Genetics or Myriad Proteomics will not be able to sell compounds, which it develops, at acceptable prices

[bodinger]

in der letzten woche (war im urlaub) hat myriad ja nen beachtlichen sprung gemacht. kennt jemand die gründe?
gruß bodinger

[heikolino]

Myriad Genetics Discovers High Cholesterol Gene
2001-06-05 06:31 (New York)


- CHD2 Enzyme is in Novel Pathway, May Lead to New Class
Of Cholesterol Lowering Drugs -

SALT LAKE CITY, June 5 /PRNewswire/ -- Myriad Genetics, Inc.
(Nasdaq: MYGN), has discovered a human gene responsible for high total
cholesterol and low HDL (also known as "good cholesterol"), in individuals
with early age myocardial infarction. The research shows that the gene`s
protein product is produced in abnormal amounts in these individuals and has
enzymatic activity and other characteristics that suggest it will be readily
amenable as a drug target. The CHD2 (Coronary Heart Disease 2) protein acts
in a novel, previously unknown pathway, distinct from the cholesterol
synthesis pathway that is acted upon by the statin class of drugs and other
classes of drugs.
The CHD2 gene, and its function, was discovered by a combination of
genetic analyses of families whose members had heart attacks at an early age
and an analysis of biological pathways. In total, more than 5,000 individuals
from 145 families were analyzed to identify the gene. The discovery in this
population, made by Myriad in collaboration with scientists from the
Cardiovascular Genetics Research Clinic at the University of Utah, means that
abnormal levels of the CHD2 protein are critical to the development of
disease. Because disorders of the CHD2 gene lead to high LDL cholesterol, low
HDL cholesterol and early-onset heart disease, inhibition of the gene with a
small molecule drug is expected to lower cholesterol and reduce the risk of
heart disease across the general population of individuals with high
cholesterol. Current therapies, including the statins, are inadequate in
lowering the total cholesterol to recommended levels in many patients. Heart
disease remains the most common cause of death in the United States. Studies
estimate that half of all men and one third of women will develop heart
disease during their lives.
"The discovery of this novel drug target for the treatment of heart
disease points to the strengths of Myriad`s integrated approach to drug
development incorporating the best technologies of genomics and proteomics in
a high-throughput, industrialized fashion," said Peter Meldrum, President and
Chief Executive Officer of Myriad Genetics, Inc. "Myriad now has a full
pipeline of earlier stage preclinical compounds to back up our lead prostate
cancer drug, which has completed a Phase IIa human clinical trial, and we
intend to aggressively advance these compounds toward commercialization."
Studies of the CHD2 gene in animal models have confirmed its role in
causing high cholesterol, which is a known risk factor for clogging of the
arteries, heart attack and stroke. Myriad is using its ProNet(R) technology
to define the disease pathway surrounding the gene and better understand the
function of the CHD2 protein and its role in the biochemical process of the
high cholesterol disorder, which leads to heart disease and stroke. Myriad
scientists found that the CHD2 gene is not involved in the cholesterol
synthesis pathway, but operates in a novel, distinct pathway that leads to
both high total cholesterol and low HDL cholesterol. Novel pathway activity
provides the potential for a new class of drugs to treat high cholesterol and
the accompanying risks of heart attack and stroke. ProNet has proven to be an
invaluable tool for both target validation and initial target identification.
"The CHD2 drug target for heart disease is now the focus of a therapeutic
development program at Myriad," said Adrian Hobden, Ph.D., President of Myriad
Pharmaceuticals, Inc. "The protein`s enzymatic function indicates that it
should be possible to block its action with a small molecule drug. Myriad has
initiated drug discovery on CHD2 and is creating assays to screen its library
of small molecules for a compound with this type of activity."
According to the American Heart Association, 100 million American adults
have total blood cholesterol values of 200 mg/dL and higher, and about
40 million American adults have levels of 240 or above. In adults, total
cholesterol levels of 240 mg/dL or higher are considered high, and levels from
200 to 239 mg/dL are considered borderline-high. Treatment with
pharmaceuticals is typically recommended for patients with total blood
cholesterol levels of over 200 mg/dL. The annual U.S. cost of treating heart
disease patients is estimated at over $325 billion.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development of novel therapeutic products derived from its proprietary genomic
and proteomic technologies. The Company has established two wholly owned
subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market
therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and
markets proprietary predictive medicine and personalized medicine products.
Myriad has established strategic alliances with Bayer, Eli Lilly, Hitachi,
Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and Syngenta.

The discussion in this news release includes forward-looking statements
that are subject to certain risks and uncertainties, including the amenability
of CHD2 as a drug target, the effect that modifying the CHD2 gene will have on
cholesterol levels and heart disease. Such statements are based on
management`s current expectations that are subject to risks and uncertainties
that could cause actual results to differ materially from those set forth or
implied by forward-looking statements, including, but not limited to
uncertainties as to the extent of future government regulation of Myriad
Genetics` business, uncertainties as to whether Myriad Genetics and its
collaborators will be successful in developing, and obtaining regulatory
approval for, and commercial acceptance of, therapeutics; the risk that
markets will not exist for therapeutic compounds that Myriad Genetics develops
or if such markets exist, that Myriad Genetics will not be able to sell
compounds, which it develops, at acceptable prices. All information in this
press release is as of June 5, 2001, and Myriad undertakes no duty to update
this information unless required by law.

[DoktorKulka]

all

warum so ruhig hier an Board???????????????

Doktorr Kukla

[Sagini]

Kann mir mal einer sagen was heute mit Myriad los ist über 15% runter was jemand News ?

DANKE im vorraus

[techno-com]

War der Kurssturz heute nur marktbedingt oder gab es da einen Grund ?? Konnte im ganzen Netz keine News finden !!!!

[[KERN]Codex]

hallo

würde mich auch interessieren, ob der kurssturz seine gründe hatte - hab aber heute zu 69€ kräftig zugelangt,
da ich denke, dass sich der kurs zumindest morgen erholen
wird!

gruß Codex

[AldoBaran]

habe auch keine wirkliche Erklärung für den Kurssturz.

Möglicherweise wurden Investoren durch die Greenpeace-Proteste gegen die
Erteilung eines Patents auf das von MYGN entdeckte Brustkrebsgen erschreckt.
Allerdings bieziehen sich die Proteste gegen die Erteilung durch das Europäische
Patentamt. Die Protete können nur Erfolg haben, wenn wichtige EU-Staaten die neue
Europäische Patentrichtlinie nicht übernehmen. Diese erlaubt auch die Patentierung
von Genen.
Augenblicklich sehe ich allerdings in den Greenpeace-Protesten bzw. in einer evtl.
Klage durch Grenpeace keine wirklichen Probleme für MYGN.

Ich hoffe, dass es bald wieder aufwärts geht.

[AldoBaran]

hier noch etwas handfesteres:


Biomed Diagnostics President: Cancer Test No Threat To Myriad

Of DOW JONES NEWSWIRES

NEW YORK -(Dow Jones)- Myriad Genetics Inc.`s (MYGN) investors shouldn`t panic over
Biomedical Diagnostics` introduction of a blood test that detects early signs of breast cancer - at least
according to Biomedical Diagnostics.

In an interview Tuesday with Dow Jones Newswires, Jim Arthur, president of privately held
Biomedical, defended the need for Myriad`s test.

"Our test is not a substitute for any of the other diagnostic tools on the market," Arthur said, adding,
"we just want to give physicians an additional tool for detecting breast cancer."

Some investors apparently did panic Monday by selling off shares of Myriad Genetics out of fear that
Biomedical`s new test, launched Friday, could render Myriad`s test - one of the company`s largest
sources of revenue - obsolete. The stock closed at $58.37 Monday, down 9%. It recently traded at
$57.15, off $1.22, or 2.1%.

But in the field of assessing breast cancer risk, there is room for plenty of testing tools, Arthur said.

"The genetic test has been thoroughly researched and should remain one of the tools in the physician`s
test-kit," he said.

Women who are genetically predisposed to breast cancer should still take Myriad`s genetic test, which
measures mutations in the gene linked to breast cancer, Arthur said.

Biomedical`s test is targeted at the 90% to 95% of women who aren`t genetically predisposed to breast
cancer. It works by measuring the amount of the protein mammastatin in women who might not benefit
from a mammogram.

"Mammograms can be an inefficient way to measure breast cancer risk in women under 40 because
their tissue is too dense for the X-ray to spot a problem," Arthur said. Biomedical`s blood test mainly
targets women under 40 years old, he said.

Eventually, Biomedical expects physicians to offer women a yearly test along with other blood tests
such as the one that measures the level of cholesterol in the blood.

Biomedical plans to start offering the test for patients of gynecologists and physicians through Esoteric
Labs, a certified custom reference lab.

The company won`t be able to sell the test directly to doctors until it gets approval from the Food and
Drug Administration. But it can`t afford to apply for approval until it receives more funding, Arthur said

[Captain_Blaubernd]

@Aldo

Danke, dass Du das Rätsel gelöst hast!

CB

[[KERN]Codex]

hallo

wenn der HERR GREENSPAN heute die Zinsen um 50 basispunkte senkt - dann wird Myriad Genetics sicherlich überproportional steigen, nach den letztlichen verlusten


gruß Codex

[Captain_Blaubernd]

Und hier eine weitere Neuigkeit, die helfen sollte, die Kursverluste der letzten Tage wieder auszubügeln:

Myriad Genetics Launches Predictive Medicine Testing in Germany, Switzerland and Austria

SALT LAKE CITY, June 27 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), has formed an exclusive collaboration with Bioscientia Ltd., an international reference laboratory company, to provide its family of BRACAnalysis(R) predictive medicine products in Germany, Switzerland and Austria, the Company announced today.

Bioscientia, based in Ingelheim, Germany is one of the largest reference laboratories in Europe, celebrating its 30th year of service emphasizing high quality, fast and accurate test results. Bioscientia employs over 900 professional and technical specialists serving university, military, and Ministry of Health hospitals, clinics, pharmaceutical companies, and over 6,000 physicians with an extensive collection and logistics network. In 2000, Bioscientia performed over 50,000 tests per workday at its Ingelheim laboratory.

"Bioscientia is a high quality esoteric testing provider and we are pleased to be working with a market leader to broaden access to our BRACAnalysis(R) tests," said Gregory Critchfield, MD, President of Myriad Genetic Laboratories, Inc. "Individuals at risk of breast cancer and ovarian cancer will have the benefit of Myriad`s tests and Bioscientia`s superb network and relationship with physicians and hospitals which we believe will assist in the prevention and medical management of these cancers. The expansion of BRACAnalysis(R) testing in Europe underscores the value of Myriad`s predictive medicine discoveries and technologies."

Under the agreement, Bioscientia will send test specimens for the comprehensive BRACAnalysis(R) full-sequence test to Myriad Genetic Laboratories in Salt Lake City for analysis. Myriad will transfer technical know-how for site-specific mutation detection to Bioscientia. Myriad and Bioscientia intend to explore opportunities for additional testing services and other ways to expand their relationship.

"Bioscientia is pleased to be working with the world leader in predictive medicine. Leveraging our international access to provide Myriad`s cancer predictive medicine tests is an important step in our goal of helping many patients and their doctors receive high quality, rapid results in order to better manage, diagnose and prevent these diseases," said Jochen Decker, M.D., Chief Executive Officer and Medical Director for Bioscientia. "As a market leader, we are constantly looking for new, world class diagnostic technologies that help fight disease. Myriad has the technology and the products that form the type of company that is a good fit with Bioscientia."

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel therapeutic products derived from its proprietary genomic and proteomic technologies. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and markets proprietary predictive medicine and personalized medicine products. Myriad has established strategic alliances with Bayer, Eli Lilly, Hitachi, Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and Syngenta.

The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties, including the sending of BRACAnalysis(R) specimens to Myriad from Bioscientia and the intention to explore additional business arrangements between Myriad and Bioscientia. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to uncertainties as to the extent of future government regulation of Myriad Genetics` business, uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices. All information in this press release is as of June 27, 2001, and Myriad undertakes no duty to update this information unless required by law.

So long,

CB

[[KERN]Codex]

moin

kurs von myriad wird gleich stark anziehen denke ich...
mal sehen wie weit wir heute laufen ?! - vielleicht ja sogar die 70€ marke?! naja news sind positiv *grins*

gruß Codex

geld/bief kurse gerade erhöht